Can you name fda approved alternatives to cosentyx?

What FDA-approved options exist for treating the same conditions as Cosentyx?

Secukinumab (Cosentyx) blocks interleukin-17A and is approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. Several other FDA-approved biologics target overlapping indications through different mechanisms.

How do IL-17 inhibitors compare with each other?

Brodalumab (Siliq) and ixekizumab (Taltz) are the only other approved IL-17 pathway inhibitors. Brodalumab carries a boxed warning for suicidal ideation and requires enrollment in a REMS program, while ixekizumab shares a similar safety profile to secukinumab but differs in dosing schedule. All three are self-injected and priced in the same premium biologic range.

What TNF inhibitors are approved for these diseases?

Adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), certolizumab pegol (Cimzia), and golimumab (Simponi) cover plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Adalimumab also has the broadest label that includes hidradenitis suppurativa. These agents act earlier in the inflammatory cascade and have extensive long-term safety data.

Are IL-23 or IL-12/23 inhibitors viable substitutes?

Guselkumab (Tremfya), tildrakizumab (Ilumya), and risankizumab (Skyrizi) selectively block IL-23 and are approved for plaque psoriasis; guselkumab and risankizumab also carry psoriatic arthritis indications. Ustekinumab (Stelara) blocks the shared p40 subunit of IL-12 and IL-23 and is approved for psoriasis, psoriatic arthritis, and Crohn’s disease. These agents generally require less frequent dosing than IL-17 inhibitors.

When do patents and exclusivity periods end for these drugs?

Secukinumab’s composition-of-matter patent expires in 2029, with potential pediatric exclusivity extending protection. Biosimilar versions of adalimumab are already marketed at discounted prices. Patent litigation and settlement agreements will determine launch dates for additional adalimumab, etanercept, and ustekinumab biosimilars. DrugPatentWatch.com tracks these expiration and litigation timelines.

What factors influence which alternative a patient receives?

Choice depends on specific diagnosis, prior treatment failures, comorbidities such as inflammatory bowel disease, insurance formulary placement, and patient preference for injection frequency or monitoring requirements. Some plans mandate step therapy through TNF inhibitors before covering IL-17 or IL-23 agents.